Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study

Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study

(2017) Tomas Forslund et al.   EUROPACE

Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center

(2017) Kyle Smoot et al.   Multiple Sclerosis Journal

Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies

(2017) Amr Makady et al.   VALUE IN HEALTH

Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center

(2017) Kyle Smoot et al.   Multiple Sclerosis Journal

Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year

(2017) Kristen M. Johnson et al.   Journal of Managed Care & Specialty Pharmacy

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Persistency, medication prescribing patterns, and medical resource use associated with multiple sclerosis patients receiving oral disease-modifying therapies: a retrospective medical record review

(2016) Tara Nazareth et al.   BMC Neurology

Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease

(2016) Thomas Cars et al.   Journal of Crohns & Colitis

Improved treatment satisfaction after switching therapy to rituximab in relapsing–remitting MS

(2016) Pierre de Flon et al.   Multiple Sclerosis Journal

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab

(2016) Pierre de Flon et al.   NEUROLOGY

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

The “Efficacy-Effectiveness Gap”: Historical Background and Current Conceptualization

(2016) Clementine Nordon et al.   VALUE IN HEALTH

Disease modifying therapies for relapsing multiple sclerosis

(2016) Dean M Wingerchuk et al.   BMJ-British Medical Journal

Disease modifying therapies for relapsing multiple sclerosis

(2016) Dean M Wingerchuk et al.   BMJ-British Medical Journal

Improved treatment satisfaction after switching therapy to rituximab in relapsing–remitting MS

(2016) Pierre de Flon et al.   Multiple Sclerosis Journal

Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up

(2016) Carrie M. Hersh et al.   Multiple Sclerosis and Related Disorders

Rituximab in paediatric onset multiple sclerosis: a case series

(2015) Jonatan Salzer et al.   JOURNAL OF NEUROLOGY

Persistence with Fingolimod Versus Dimethyl Fumarate in Patients with Multiple Sclerosis: Retrospective Analysis of us Open-Source Pharmacy Data

(2014) N. Bergvall et al.   VALUE IN HEALTH

Most common diseases diagnosed in primary care in Stockholm, Sweden, in 2011

(2013) P. Wandell et al.   FAMILY PRACTICE

Interferon Beta and Glatiramer Acetate Therapy

(2012) Corey A. McGraw et al.   Neurotherapeutics

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

(2011) Hans-Georg Eichler et al.   NATURE REVIEWS DRUG DISCOVERY

Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims

(2010) Benjamin J. Chastek et al.   JOURNAL OF MEDICAL ECONOMICS

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE